Year: 2014
Type: article
Abstract: The ubiquitin proteasome system (UPS) is an essential metabolic constituent of cellular physiology that tightly regulates cellular protein concentrations with specificity and precision to optimize cellular function. Inhibition of the proteasome has proven very effective in the treatment of multiple myeloma, and this approach is being tested for utility in other malignancies. New pharmaceuticals targeting the proteasome itself or specific proximal pathways of the UPS are in development as antiproliferatives or immunomodulatory agents. In this article, we discuss the biology of UPS-targeting drugs, their use as therapy for neoplasia, and the state of clinical and preclinical development for emerging therapeutics.
DOI: 10.1172/jci71602
Institutions: University of Pittsburgh, VA Pittsburgh Healthcare System
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: bronze
Awards: Regulation of the interferon lamda receptor by influenza, Stabilizing mitochondria in sepsis, G5520316217, G5728561071, G7209639321, A New Genus of Ubiquitin-Based Anti-inflammatories for COPD, Immunosuppression in Acute Lung Injury, Sepsis-Associated Immune Suppression and F-box Proteins, E3 Ligase-Mediated Immunosuppression in Acute Lung Injury
OpenAlex ID: W2016521092
